Analysts project big rise in Alzheimer's drug market; Regeneron profits continue to rise;

@FierceBiotech: FierceBiotech Radio with Editas Medicine's Katrine Bosley. More | Follow @FierceBiotech

@JohnCFierce: So the operational word for biotech valuations now seems to be 'frothy.' We blew past frothy months ago and now are at 'dizzying.' | Follow @JohnCFierce

> GlobalData believes that a wave of high-risk Alzheimer's drugs now in the clinic will go on to approval, spurring a rapid rise in that market sector that will take overall sales from $4.9 billion to $13 billion by 2023. Report

> Growing sales of Eylea pushed quarterly profit up 11% at Regeneron. Story

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: Agilent acquires maker of software for diagnostics laboratories. Report | Follow @FierceMedDev

@VarunSaxena2: NIH says viral vector for delivering gene therapy to treat blindness shows promise, Wall Street less sure. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Theranos hired a former Clinton policy adviser as its top lawyer. Bloomberg story | Follow @EmilyWFierce

> Medtronic aims to push insertion of world's tiniest cardiac monitor into the physicians' office. More

> Startup Moximed gets $33M to gain FDA approval of early stage osteoarthritis knee implant. Article

Pharma News

@FiercePharma: The FDA Is On A Quest To Rid DTC Drug Ads Of Confounding Fine Print. Forbes article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Billionaire supporter Paulson could help Teva twist Mylan's arm. Report | Follow @CarlyHFierce

> Pharma dealmaking boosts M&A to record-setting heights in Q1. Story

> Big Pharma's cardiovascular sales ain't what they used to be. Report

CRO News

> Biocon's planned CRO IPO could change the tone in India. Item

> Catalent boosts its profits despite some flat revenue. More

> AMRI swings to another loss despite big sales gains. Story

> Quintiles beefs up in bioanalytics ahead of Quest partnership. Article

> Parexel trims its ambitions after a flat quarter. Report

Vaccines News

> Themis rounds up new cash for Chikungunya jab's PhII. News

> Three universities using $1.55M NIH grant to track vaccine attitudes via Twitter. Item

> GSK's vaccine operating profit, margin dive on Novartis fold-in. Story

> Sanofi promises 7% vax sales growth for 2015, despite rocky Q1. Report

> City of Hope, Fortress Biotech form new company to ward off CMV. Article

Pharma Manufacturing News

> Biosimilar manufacturers form group to influence market in U.S. Item

> Hospira whacks first 100 jobs as it shutters Clayton, NC, plant. More

> BASF selling some APIs, three plants to Siegfried. Report

> FDA makes strides in inspection effort but challenges persist. Story

> Manufacturing moves pay off for AMRI. Article

Pharma Asia News

> China kicks press into high gear to knock down talk on higher drug prices. More

> Australia budget is a showdown on cancer drug funding, safety net reach. Report

> Taiwan device maker Apex invests in India and plans more. More

> Afghan battlefield clotting agent makes a comeback in Russia. Article

> Sumitomo Dainippon, Takeda call it quits on Japan Latuda agreement. Story

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.